Reading -18th July 2014: Basilea Pharmaceutica Ltd. has recently reported that the European Commission granted isavuconazole orphan drug designations for the treatment of invasive aspergillosis and mucormycosis (zygomycosis). Isavuconazole is an investigational intravenous and oral broad-spectrum antifungal.
TranScrip Partners provided regulatory and medical writing support to Basilea in preparing the orphan drug application and during the orphan designation procedure and are delighted to learn of this important development.
Deputy Managing Partner of TranScrip, Dr. Marcin Mankowski said “TranScrip have been providing support to Basilea in their isavuconazole orphan drug application and we are delighted to see the successful designation. It further cements our reputation in helping deliver successful outcomes for our clients.”
To view the full details of the original Basilea news release please click here.